Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SRPT)

Option Trade Reports for Comcast, Southwest Airlines Co., Sarepta Therapeutics, Toronto-Dominion Bank and Weight Watchers from InvestorsObserver

PR Newswire January 27, 2017

FDA 101: What Does 'Orphan Drug Designation' Mean?

Benzinga.com January 17, 2017

Investors: Covered-Call Reports for Boston Scientific Corporation, eBay, MGM Resorts, Sarepta Therapeutics and Williams Companies

PR Newswire January 11, 2017

Sarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Children’s Hospital for Microdystrophin Gene Therapy Program

Business Wire January 10, 2017

Sarepta Therapeutics Enters into License Agreement with Nationwide Children’s Hospital for Galgt2 Gene Therapy Program

Business Wire January 10, 2017

Sarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2017

Watch These 8 Huge Call Purchases In Tuesday Trade

Benzinga.com January 3, 2017

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 30, 2016

Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week

Benzinga.com December 27, 2016

Where Does Merck's Ebola Vaccine Breakthrough Leave Competitors?

Benzinga.com December 23, 2016

The Market In 5 Minutes: BlackBerry, Nike Earnings In Focus

Benzinga.com December 20, 2016

Sarepta Therapeutics Announces EMA Validation of Eteplirsen Authorization Application for Treatment of Duchenne Muscular Dystrophy Amenable to Exon Skipping 51

Business Wire December 19, 2016

Sarepta's Launch Of Exondys 51 Likely Slower Than Expected As Payers Deny Or Restrict Coverage

Benzinga.com December 14, 2016

How These Biotech Stocks are Faring? -- Celgene, Sarepta Therapeutics, MannKind and Amgen

PR Newswire December 6, 2016

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 30, 2016

Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th Annual Healthcare Conference

Business Wire November 4, 2016

Watch These 5 Huge Put Purchases In Tuesday Trade

Benzinga.com November 1, 2016

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 31, 2016

Sarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate Developments

Business Wire October 27, 2016

Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate Developments on October 27, 2016

Business Wire October 24, 2016